Phase III Randomized Adjuvant Study of MK-3475 Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma AMBASSADOR versus Observation
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative with Evident Efficacy in Patients with Muscle Invasive Bladder Cancer
A Randomized Phase II Study of Erdafitinib Versus Investigator Choice of Intravesicular Chemotherapy in Subjects Who Received Bacillus Calmette-Gu�rin BCG and Progressed or Recurred With High Risk Non-Muscle-Invasive Bladder Cancer NMIBC and FGFR Mutations or Fusions
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer NIAGARA
Phase I/II Open-Label Study to Evaluate the Safety and Preliminary Efficacy of Mrx0518 in Combination with Pembrolizumab in Patients with Non-Small-Cell Lung Cancer, Renal Cell Carcinoma, Bladder Cancer, and Melanoma Who Have Progressed on PD-1 Inhibitors